Testing effectiveness (Phase 2)Study completedNCT04509791
What this trial is testing
MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Who this might be right for
Diabetes Mellitus, Type 1
Universitaire Ziekenhuizen KU Leuven 114